Sharon Bio-Medicine Ltd

Sharon Bio-Med. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Sharon Bio-Medicine Ltd

₹ 3.30 -4.35%
28 Mar 2019
sharonbio.com
About

Sharon Bio-Medicine Limited is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and commercialization of pharmaceutical products. The Company operates in three segments, which include Active Pharma Ingredients (API's), Formulations and Toxicology.

[ add key points ]
Website
  • Market Cap ₹ 39.2 Cr.
  • Current Price ₹ 3.30
  • High / Low ₹ /
  • Stock P/E
  • Book Value ₹ -15.3
  • Dividend Yield 0.00 %
  • ROCE -17.0 %
  • ROE -269 %
  • Face Value ₹ 2.00
Edit ratios

Pros

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -13.5% over past five years.
  • Company has a low return on equity of -17.3% over last 3 years.
  • Company has high debtors of 264 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Jun 2013 Sep 2013 Dec 2013 Mar 2014 Jun 2014 Sep 2014 Dec 2014 Mar 2015 Jun 2015 Sep 2015 Dec 2015 Mar 2016
276 325 319 340 318 350 326 238 130 490 113 105 36
244 292 284 301 279 305 287 314 133 472 109 103 176
Operating Profit 33 33 35 39 39 44 39 -76 -3 18 4 2 -140
OPM % 12% 10% 11% 11% 12% 13% 12% -32% -2% 4% 4% 2% -392%
0 0 -1 -1 -1 -0 1 -15 -33 1 -58 -50 38
Interest 11 11 11 14 14 14 14 17 13 46 17 18 36
Depreciation 3 4 4 4 4 3 3 3 8 0 5 5 5
Profit before tax 18 18 19 20 20 27 23 -111 -56 -26 -76 -71 -144
Tax % 18% 19% 18% 17% 10% 24% 0% -3% 0% 18% 0% 0% 7%
15 15 16 16 18 21 23 -108 -56 -31 -76 -71 -154
EPS in Rs 1.43 1.42 1.48 1.54 1.71 1.95 2.16 -10.20 -5.03 -2.60 -6.37 -5.95 -12.93
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Jun 2008 Jun 2009 Jun 2010 Jun 2011 Jun 2012 Jun 2013 Jun 2014 Jun 2015 Mar 2016 9m
335 420 523 627 804 1,074 1,325 838 253
296 381 468 554 708 952 1,167 873 387
Operating Profit 39 39 55 72 96 121 158 -34 -134
OPM % 12% 9% 10% 12% 12% 11% 12% -4% -53%
2 2 0 1 1 1 2 -82 -70
Interest 7 14 21 27 34 43 59 94 71
Depreciation 4 4 6 8 9 12 15 19 15
Profit before tax 31 22 28 38 54 67 85 -229 -290
Tax % 13% 16% 19% 14% 21% 20% 18% 2% 3%
27 19 22 33 43 54 70 -234 -300
EPS in Rs 2.58 1.77 2.12 3.15 4.05 5.09 6.66 -19.67 -25.25
Dividend Payout % 5% 7% 6% 0% 4% 0% 5% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: -13%
3 Years: -32%
TTM: -81%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -427%
Stock Price CAGR
10 Years: -12%
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: -3%
3 Years: -17%
Last Year: -269%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Jun 2008 Jun 2009 Jun 2010 Jun 2011 Jun 2012 Jun 2013 Jun 2014 Jun 2015 Mar 2016
Equity Capital 11 11 11 11 11 11 21 24 24
Reserves 78 96 116 194 189 241 331 95 -205
214 262 343 344 508 644 725 821 836
26 29 42 48 74 84 92 72 68
Total Liabilities 330 397 512 596 781 980 1,169 1,012 723
57 56 184 181 201 272 325 332 319
CWIP 44 107 23 27 60 43 15 0 0
Investments 1 1 3 3 3 3 1 0 0
229 234 302 385 517 662 829 680 404
Total Assets 330 397 512 596 781 980 1,169 1,012 723

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Jun 2008 Jun 2009 Jun 2010 Jun 2011 Jun 2012 Jun 2013 Jun 2014 Jun 2015 Mar 2016
-40 -51 -28 -36 -53 -70 -70 -84 -31
-41 -65 -51 -8 -61 -64 -27 -10 -0
154 47 78 46 117 134 103 97 26
Net Cash Flow 72 -69 -1 1 2 0 6 4 -6
Free Cash Flow -80 -122 -78 -46 -116 -136 -101 -94 -33
CFO/OP -104% -94% -13% -50% -56% -58% -44% 243% 24%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Jun 2008 Jun 2009 Jun 2010 Jun 2011 Jun 2012 Jun 2013 Jun 2014 Jun 2015 Mar 2016
Debtor Days 104 116 119 118 122 124 116 138 264
Inventory Days 74 90 96 108 106 104 105 135 198
Days Payable 8 23 28 25 27 24 20 25 44
Cash Conversion Cycle 170 183 188 202 201 203 201 248 418
Working Capital Days 142 176 182 73 80 74 83 127 68
ROCE % 11% 12% 13% 14% 14% 15% -5% -17%

Insights

In beta
Mar 2015 Mar 2016 Jan 2018 Mar 2019 Jun 2020
Number of Manufacturing Facilities
Numbers ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Number of R&D Centres
Numbers ・Standalone data
API Capacity Utilization
% ・Standalone data
API Reactor Capacity
Liters ・Standalone data
Formulations Capacity Utilization
% ・Standalone data
Formulations Installed Capacity (Tablets & Capsules)
Million Units ・Standalone data
R&D Expenditure
INR Lacs ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023
32.53% 32.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
0.01% 0.01% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02%
67.46% 67.46% 99.97% 99.97% 99.98% 99.97% 99.97% 99.97% 99.97% 99.99% 99.99% 99.98%
No. of Shareholders 24,83624,83024,85424,85424,85424,85424,85424,85424,85324,83724,83724,837

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

No data available.

Annual reports

Credit ratings